BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Boston
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T083000
DTEND;TZID=America/New_York:20191210T130000
DTSTAMP:20260716T073942
CREATED:20191125T155225Z
LAST-MODIFIED:20191125T155225Z
UID:7324-1575966600-1575982800@scienceinboston.com
SUMMARY:The Diversity & Inclusion Forum: Perspectives & Possibilities for the Life Science Industry
DESCRIPTION:Overview\n\nMassBio\, in partnership with SVB Leerink\, WEST and  Silicon Valley Bank is hosting an invite-only event to bring together the best and brightest minds in the life sciences and healthcare industry for a thoughtful discussion on how we can make our workforce\, workplace\, and marketplace more inclusive. You will hear from thought-provoking industry leaders\, enjoy interactive sessions with actionable insights to positively impact our community\, and benefit from meaningful networking opportunities to encourage good diversity of thought. \nPlease email Edie Stringfellow if you are interested in attending. \n\nOur Workforce – Who we hire and how we hire matters. How do we build I&D into our workforce by focusing on our hiring practices and hiring decisions\, the processes we undertake to evaluate potential employees and where we go to recruit them etc.?\nOur Workplace – Once we’ve hired great people\, how do we keep and develop them?\nOur Marketplace – How do we become more deliberate to ensure the diverse perspectives and needs of our customers and communities are taken into consideration?\n\nWe hope to help change views from having D&I being seen as a challenge\, to being embraced as an invaluable opportunity to make our employees\, our business\, and our industry stronger. Click here for more details\, full agenda and speaker information. \n  \nDate: \nTuesday\, December 10\, 2019\n8:30 a.m. – 1:00 p.m. \nAdd to My Calendar \n  \nLocation: \nConvene \n201 Washington Street\, 2nd Floor \nBoston\, MA 02108
URL:https://scienceinboston.com/event/the-diversity-inclusion-forum-perspectives-possibilities-for-the-life-science-industry/
LOCATION:Convene\, 201 Washington Street\, 2nd Floor\, Boston\, MA\, 02108\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T083000
DTEND;TZID=America/New_York:20191210T130000
DTSTAMP:20260716T073942
CREATED:20191125T155225Z
LAST-MODIFIED:20191125T155225Z
UID:27400-1575966600-1575982800@scienceinboston.com
SUMMARY:The Diversity & Inclusion Forum: Perspectives & Possibilities for the Life Science Industry
DESCRIPTION:Overview\n\nMassBio\, in partnership with SVB Leerink\, WEST and  Silicon Valley Bank is hosting an invite-only event to bring together the best and brightest minds in the life sciences and healthcare industry for a thoughtful discussion on how we can make our workforce\, workplace\, and marketplace more inclusive. You will hear from thought-provoking industry leaders\, enjoy interactive sessions with actionable insights to positively impact our community\, and benefit from meaningful networking opportunities to encourage good diversity of thought. \nPlease email Edie Stringfellow if you are interested in attending. \n\nOur Workforce – Who we hire and how we hire matters. How do we build I&D into our workforce by focusing on our hiring practices and hiring decisions\, the processes we undertake to evaluate potential employees and where we go to recruit them etc.?\nOur Workplace – Once we’ve hired great people\, how do we keep and develop them?\nOur Marketplace – How do we become more deliberate to ensure the diverse perspectives and needs of our customers and communities are taken into consideration?\n\nWe hope to help change views from having D&I being seen as a challenge\, to being embraced as an invaluable opportunity to make our employees\, our business\, and our industry stronger. Click here for more details\, full agenda and speaker information. \n  \nDate: \nTuesday\, December 10\, 2019\n8:30 a.m. – 1:00 p.m. \nAdd to My Calendar \n  \nLocation: \nConvene \n201 Washington Street\, 2nd Floor \nBoston\, MA 02108
URL:https://scienceinboston.com/event/the-diversity-inclusion-forum-perspectives-possibilities-for-the-life-science-industry-2/
LOCATION:Convene\, 201 Washington Street\, 2nd Floor\, Boston\, MA\, 02108\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T100000
DTEND;TZID=America/New_York:20191210T150000
DTSTAMP:20260716T073942
CREATED:20191125T155440Z
LAST-MODIFIED:20191125T155440Z
UID:7328-1575972000-1575990000@scienceinboston.com
SUMMARY:Engaging with Pharma Partners
DESCRIPTION:Overview\n\nJoin us at M2D2 for discussion around how and when startups should engage with pharma partners. Learn tips\, best practices\, and take advantage of great networking. Lunch will be provided. \n  \nAgenda: \n10:00- Check-in\, Welcome & Introductions \n10:30-11:45 – Panel presentation \n11:45-1:00 – Lunch & Networking \n1:00-3:00 – Optional private 1:1 meeting \n  \nConfirmed: \n  \nImran Nasrullah – Boehringer Ingelheim \n  \nOutcome driven biopharmaceutical leader\, recognized for delivering innovation and being creative\, dynamic\, and cross functionally capable. Recipient of Boehringer Ingelheim’s President Award. Extensive experience covering business development\, alliance management\, partnering and licensing activities in diagnostics\, personalized medicine\, therapeutics\, and technology platforms with proven track record from Boehringer Ingelheim\, Massbio\, Genzyme Genetics\, Millennium Pharmaceuticals. \n  \nAlex Lagadinos – Sarepta \n  \n  \nPhD trained molecular biologist with an MBA-level education in bioscience management and over 10 years of experience in research and development. Proven track record of bridging discovery research with business development in order to align strategic initiatives and promote corporate development. Experience with inbound and outbound collaborative transactions and tacit knowledge in rare diseases. \n  \nJennifer Ma – Novartis Institutes for BioMedical Research (NIBR) \n  \nJennifer joined the Novartis Institutes for BioMedical Research (NIBR) in 2015 focusing on licensing and transactions. NIBR is the early R&D unit of Novartis\, responsible for programs from drug discovery stage through early clinical development\, covering all the therapeutic interest areas for Novartis. The licensing team establishes diverse kinds of collaborations with biotech companies and academics. Prior to joining NIBR\, Jennifer held progressively more senior business and licensing roles at AstraZeneca/Medimmune and 5AM Ventures\, and started her career setting up a Novartis-academic spin-out. She received a B.A. in Chemistry from Harvard University\, a Ph.D. in organic chemistry from the California Institute of Technology\, and an M.B.A. from Harvard Business School.
URL:https://scienceinboston.com/event/engaging-with-pharma-partners/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T100000
DTEND;TZID=America/New_York:20191210T150000
DTSTAMP:20260716T073942
CREATED:20191125T155440Z
LAST-MODIFIED:20191125T155440Z
UID:27401-1575972000-1575990000@scienceinboston.com
SUMMARY:Engaging with Pharma Partners
DESCRIPTION:Overview\n\nJoin us at M2D2 for discussion around how and when startups should engage with pharma partners. Learn tips\, best practices\, and take advantage of great networking. Lunch will be provided. \n  \nAgenda: \n10:00- Check-in\, Welcome & Introductions \n10:30-11:45 – Panel presentation \n11:45-1:00 – Lunch & Networking \n1:00-3:00 – Optional private 1:1 meeting \n  \nConfirmed: \n  \nImran Nasrullah – Boehringer Ingelheim \n  \nOutcome driven biopharmaceutical leader\, recognized for delivering innovation and being creative\, dynamic\, and cross functionally capable. Recipient of Boehringer Ingelheim’s President Award. Extensive experience covering business development\, alliance management\, partnering and licensing activities in diagnostics\, personalized medicine\, therapeutics\, and technology platforms with proven track record from Boehringer Ingelheim\, Massbio\, Genzyme Genetics\, Millennium Pharmaceuticals. \n  \nAlex Lagadinos – Sarepta \n  \n  \nPhD trained molecular biologist with an MBA-level education in bioscience management and over 10 years of experience in research and development. Proven track record of bridging discovery research with business development in order to align strategic initiatives and promote corporate development. Experience with inbound and outbound collaborative transactions and tacit knowledge in rare diseases. \n  \nJennifer Ma – Novartis Institutes for BioMedical Research (NIBR) \n  \nJennifer joined the Novartis Institutes for BioMedical Research (NIBR) in 2015 focusing on licensing and transactions. NIBR is the early R&D unit of Novartis\, responsible for programs from drug discovery stage through early clinical development\, covering all the therapeutic interest areas for Novartis. The licensing team establishes diverse kinds of collaborations with biotech companies and academics. Prior to joining NIBR\, Jennifer held progressively more senior business and licensing roles at AstraZeneca/Medimmune and 5AM Ventures\, and started her career setting up a Novartis-academic spin-out. She received a B.A. in Chemistry from Harvard University\, a Ph.D. in organic chemistry from the California Institute of Technology\, and an M.B.A. from Harvard Business School.
URL:https://scienceinboston.com/event/engaging-with-pharma-partners-2/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T110000
DTEND;TZID=America/New_York:20191210T130000
DTSTAMP:20260716T073942
CREATED:20191125T155713Z
LAST-MODIFIED:20191125T155733Z
UID:7330-1575975600-1575982800@scienceinboston.com
SUMMARY:Using Machine Learning and Other Methods to Build Predictive QSAR Models
DESCRIPTION:Overview\n\nThis hands-on workshop will focus on using Forge™\, Cresset’s methods for developing 3D and 2D-QSAR models. We will show how to easily apply SVM\, RVM\, Random Forest\, and kNN methods to build multiple models and choose between them; interpret 3D-QSAR models to explain observed SAR; use the models to predict activity for new compound design; use the visual feedback to improve compound design. \nHands-on: If you wish to follow along in this hands-on workshop then please bring a laptop (a download link to Forge will be provided before the event if needed). \nWho should attend: Computational chemists. Some familiarity with alignment in Forge an advantage.
URL:https://scienceinboston.com/event/using-machine-learning-and-other-methods-to-build-predictive-qsar-models/
LOCATION:CIC\, Charles Room\, 14th Floor\, CIC\, 1 Broadway\, Cambridge\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T110000
DTEND;TZID=America/New_York:20191210T130000
DTSTAMP:20260716T073942
CREATED:20191125T155713Z
LAST-MODIFIED:20191125T155713Z
UID:27402-1575975600-1575982800@scienceinboston.com
SUMMARY:Using Machine Learning and Other Methods to Build Predictive QSAR Models
DESCRIPTION:Overview\n\nThis hands-on workshop will focus on using Forge™\, Cresset’s methods for developing 3D and 2D-QSAR models. We will show how to easily apply SVM\, RVM\, Random Forest\, and kNN methods to build multiple models and choose between them; interpret 3D-QSAR models to explain observed SAR; use the models to predict activity for new compound design; use the visual feedback to improve compound design. \nHands-on: If you wish to follow along in this hands-on workshop then please bring a laptop (a download link to Forge will be provided before the event if needed). \nWho should attend: Computational chemists. Some familiarity with alignment in Forge an advantage.
URL:https://scienceinboston.com/event/using-machine-learning-and-other-methods-to-build-predictive-qsar-models-2/
LOCATION:CIC\, Charles Room\, 14th Floor\, CIC\, 1 Broadway\, Cambridge\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T160000
DTEND;TZID=America/New_York:20191210T180000
DTSTAMP:20260716T073942
CREATED:20191125T155941Z
LAST-MODIFIED:20191125T155941Z
UID:7334-1575993600-1576000800@scienceinboston.com
SUMMARY:Value Of Health Part III: Potential Disruptors' Impact To Value\, Access & Reimbursement
DESCRIPTION:This event\, Part III in a three part series that will explore the value of health\, will consider disruptions to the ever-evolving value\, access & reimbursement landscape as new players enter the arena and others consolidate. What impact will mergers between payers and PBMs have on drug pricing\, patient access\, and the ability to track and analyze data? How are digital technologies changing the way we track patients and ensure access? What impact will one-time cures have on the system? What new financing methodologies are gaining traction and what else can we do to support their widespread adoption?  What new players are disrupting the value equation? We’ll attempt to answer those questions and more\, with MassBio’s Bob Coughlin as the moderator. \nWe believe this issue is especially timely. We’re at an inflection point\, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action\, and healthcare stakeholders agreeing that we must come up with real solutions. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies\, government or other stakeholders will – and they will likely get it wrong. \nDrinks and appetizers will be provided. If you’re not a MassBio member but are interested in attending\, please email contact us at communications@massbio.org.
URL:https://scienceinboston.com/event/value-of-health-part-iii-potential-disruptors-impact-to-value-access-reimbursement/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T160000
DTEND;TZID=America/New_York:20191210T180000
DTSTAMP:20260716T073942
CREATED:20191125T155941Z
LAST-MODIFIED:20191125T155941Z
UID:27403-1575993600-1576000800@scienceinboston.com
SUMMARY:Value Of Health Part III: Potential Disruptors' Impact To Value\, Access & Reimbursement
DESCRIPTION:This event\, Part III in a three part series that will explore the value of health\, will consider disruptions to the ever-evolving value\, access & reimbursement landscape as new players enter the arena and others consolidate. What impact will mergers between payers and PBMs have on drug pricing\, patient access\, and the ability to track and analyze data? How are digital technologies changing the way we track patients and ensure access? What impact will one-time cures have on the system? What new financing methodologies are gaining traction and what else can we do to support their widespread adoption?  What new players are disrupting the value equation? We’ll attempt to answer those questions and more\, with MassBio’s Bob Coughlin as the moderator. \nWe believe this issue is especially timely. We’re at an inflection point\, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action\, and healthcare stakeholders agreeing that we must come up with real solutions. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies\, government or other stakeholders will – and they will likely get it wrong. \nDrinks and appetizers will be provided. If you’re not a MassBio member but are interested in attending\, please email contact us at communications@massbio.org.
URL:https://scienceinboston.com/event/value-of-health-part-iii-potential-disruptors-impact-to-value-access-reimbursement-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
END:VCALENDAR